Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 341

Results For "Act"

8041 News Found

Sterling Biotech and Zydus Lifesciences agree to extend completion of business transfer
News | December 28, 2024

Sterling Biotech and Zydus Lifesciences agree to extend completion of business transfer

Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025


Shilpa Medicare's Unit IV receives Eurasia GMP approval
Drug Approval | December 28, 2024

Shilpa Medicare's Unit IV receives Eurasia GMP approval

Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia


Fortis Healthcare appoints Leo Puri as Chairman of the Board
People | December 28, 2024

Fortis Healthcare appoints Leo Puri as Chairman of the Board

Puri is an accomplished leader and financial sector veteran with over four decades of experience


Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
News | December 27, 2024

Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab

Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India


Thyrocare secures NABL accreditation for its Labs
News | December 27, 2024

Thyrocare secures NABL accreditation for its Labs

Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation


Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
Drug Approval | December 27, 2024

Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia

GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH


Akums signs Rs. 1,760 crore CDMO agreement with a leading global pharma company
News | December 26, 2024

Akums signs Rs. 1,760 crore CDMO agreement with a leading global pharma company

The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities


Aarti Drugs receives EIR from USFDA for Tarapur API facility
Drug Approval | December 26, 2024

Aarti Drugs receives EIR from USFDA for Tarapur API facility

This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP